Methods of Analyzing Pathways of Colorectal Cancer in Middle East May Be Ineffective

Share this content:

the Cancer Therapy Advisor take:

A majority of Middle Eastern colorectal cancer (CRC) cases was designated as part of the unassigned group, suggesting methods of analyzing molecular pathways may not apply to this ethnic group, according to an article published online in the journal Cancer.

A total of 770 CRC cases were evaluated using molecular characterization for microsatellite instability, BRAF, and KRAS by polymerase chain reaction, and another 500 cases were examined for CpG island methylator phenotype (CIMP) high phenotype.

Results showed 33.4% of CRC cases were comprised of the traditional pathway, 11.6% were the alternate pathway, and 0.8% of CRC cases in the Middle East were characterized as the serrated molecular pathway. The remaining 54.2% of CRC cases were not characterized according to any of the three molecular pathways, and, therefore, they were categorized as the unassigned group.

Furthermore, the molecular pathways were determined to be significantly associated with both tumor site and grade.

A significant survival difference (P=0.0079) was observed in a subset of cases with an unassigned molecular pathway.

The study’s findings suggest that more research is needed regarding the molecular genetic basis of CRC in order to characterize cases of the disease. 

Cancer of Unknown Origin: A Diagnostic and Treatment Dilemma
A majority of Middle Eastern colorectal cancer cases was designated as part of the unassigned group.
Beg, S., Siraj, A. K., Prabhakaran, S., Bu, R., Al-Rasheed, M., Sultana, M., Qadri, Z., Al-Assiri, M., Sairafi, R., Al-Dayel, F., Al-Sanea, N., Uddin, S. and Al-Kuraya, K. S. (2015), Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. Cancer. doi: 10.1002/cncr.29580
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs